

Docket No.: 064804-0054



PATENT

[Handwritten signature]

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Customer Number: 20277
Eli WALLACE, et al. : Confirmation Number: 2454
Application No.: 10/642,440 : Group Art Unit: 1624
Filed: August 14, 2003 : Examiner: JARRELL, NOBLE E
For: QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.


11/05/2007 DEMMANU1 00000125 500417 10642440
01 FC:1806 180.00 DA

In accordance with 37 CFR 1.17(p), please charge the fee of \$180.00 to Deposit Account No. 500417.

Please charge any shortage in fees due in connection with the filing of this paper, including extension of time fees, to Deposit Account 500417 and please credit any excess fees to such deposit account.

Respectfully submitted,

McDERMOTT WILL & EMERY LLP



Brian K. Seidleck
Registration No. 51,321

600 13th Street, N.W.
Washington, DC 20005-3096
Phone: 202.756.8000 BKS:aej
Facsimile: 202.756.8087
Date: November 2, 2007

**Please recognize our Customer No. 20277
as our correspondence address.**